• Bloomberg


Takeda Pharmaceutical Co., Japan’s largest drugmaker, forecast its biggest jump in full-year profit in six years on sales of the best-selling Actos diabetes pill.

Net income will rise 18 percent to ¥395 billion in the year ending March 31, from ¥335.8 billion a year earlier, the Osaka-based company said Monday. Actos overtook GlaxoSmithKline PLC’s Avandia as the world’s top-selling diabetes medicine after the Glaxo drug was linked in a May 21 report to a higher heart attack risk.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.